News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News GSK wins the vote contest in FDA’s RSV vaccine panels Advisory committee votes unanimously that RSVPreF3 shot is effective, and 10-2 on safety.
News Pfizer’s RSV shot clears FDA adcomm; now it’s GSK’s turn There was debate about cases of Guillain Barré and the population of the phase 3 RENOIR trial.
News Protocol violations gut Pfizer’s Lyme disease shot study 50% of US patients in the VALOR study of VLA15 will be discontinued from the trial.
Oncology Partner Content 2nd Next Generation RNA Therapeutics Summit Bringing Next Generation RNA Therapies to Patients Fast
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
